BIS §232 Pharma Guidance, Specialty Pharmaceuticals Eligible for Zero Tariff Under Proclamation 11020

The Bureau of Industry and Security issued guidance defining specialty pharmaceutical products and qualifying jurisdictions eligible for a zero ad valorem tariff rate under §232 Proclamation 11020 (April 2, 2026). Eligible products include orphan-designated drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell/gene therapies, antibody drug conjugates, CBRN medical countermeasures, and...